Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514079000 Nitrogen containing hetero ring 952
514114000 Nitrogen, other than nitro or nitroso, bonded indirectly to phosphorus 202
514077000 Inner salt (e.g., betaine, etc.) 125
514102000 Two or more phosphorus atoms directly or indirectly bonded together by only covalent bonds 125
514120000 C=O other than as ketone or aldehyde, attached directly or indirectly to phosphorus 80
514099000 Oxygen containing hetero ring 72
514129000 Oxygen bonded directly to a carbon or hydrogen and wherein the oxygen is not bonded directly to phosphorus 54
514143000 Ester of (HX)P=X(XH)(XH) (X is chalcogen) (e.g., phosphate, etc.) 32
514110000 Phosphorus is part of a ring 25
514125000 Ketone or aldehyde containing 15
514095000 Sulfur containing hetero ring 12
514141000 (CX-) (C)P=X(XH) or (CX-) (R)P=X(XC) containing (e.g., phosphonate, etc.) (X is chalcogen; R is C or H) 10
514126000 Sulfur not bonded directly to phosphorus 9
514076000 Amine addition salt of organic phosphorus containing acid 8
514112000 Cyano or isocyano containing 7
514134000 Acyclic carbon to carbon unsaturation 6
514140000 (C)(R)P=X(-XC) containing (i.e., Phosphinate (X is chalcogen; R is C or H) 3
20100273745POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS - Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1.10-28-2010
20100298276THYROID RECEPTOR LIGANDS - Thyroid receptor ligands are provided which have the general formula I11-25-2010
20150320047PESTICIDE COMPOSITION COMPRISING FOSETYL-ALUMINIUM, PROPAMOCARB-HCL AND AN INSECTICIDE ACTIVE SUBSTANCE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.11-12-2015
514137000 Nitrogen bonded directly to phosphorus 3
20090105196USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS - Creatine compounds for the treatment of dermatitis are described.04-23-2009
20100075927CHEMOTHERAPEUTIC CONJUGATES AND METHODS OF USE - Chemotherapeutic conjugates of a peptide substrate to a phosphoramide chemotherapeutic agent in which a peptide substrate is covalently linked to the chemotherapeutic agent by a linker with an aminoarylmethyl or aminoheteroaryl moiety, wherein the linking of the peptide to the chemotherapeutic agent inhibits the cytotoxic activity of the chemotherapeutic agent, the peptide is a substrate for proteolytic cleavage by a tumor-specific enzyme; and the linker is capable of undergoing 1,6-elimination in vivo upon cleavage of the peptide substrate. Methods for synthesizing and methods of using the conjugates are also disclosed.03-25-2010
20120035141CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.02-09-2012
514142000 (CX-)(C)P(C),(CX-)(RX-)P(C),(CX-)P(XH)(XH) or (CX-)(CX-)P(-XR) containing (X is chalcogen; R is C or H) (e.g., phosphinite, phosphite, etc.) 2
20080207567Treatment of Hcv Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).08-28-2008
20110263538COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES - The present invention provides a composition for controlling plant diseases comprising, as active ingredients, ethaboxam and tolclofos-methyl.10-27-2011
514131000 Nitro group bonded to a carbon 2
20100093671NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.04-15-2010
20100099649SITE-SPECIFIC CHEMICAL MODIFICATION OF PROTEINS AT THEIR N-TERMINI, ENABLING THE FORMATION OF HOMOGENEOUS ADDUCTS - Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of disorders such as cancer, Crohn's disease, arthritis, atherothrombosis and plaque rupture are also provided.04-22-2010
514109000 P-X-X containing (X is chalcogen) 1
20120108550Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments - Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.05-03-2012
Entries
DocumentTitleDate
20080261922Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists - This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.10-23-2008
20080275003Bis-Cationic Compounds and Use Thereof - The present invention relates to bis-cationic compounds comprising quaternary ammonium groups and/or quaternary phosphonium groups. The invention also relates to the use of bis-cationic compounds as Phospholipase B inhibitors and the use of bis cationic compounds for the treatment or prevention of microbial infection.11-06-2008
20090036407FLEA CONTROL METHOD - This invention relates to a method of controlling or preventing maturation of fleas on an animal or its environment comprising applying to a warm blooded animal or its environment a composition comprising an developmentally disruptive amount of a compound of Formula 1 or an N-oxide, or a salt thereof.02-05-2009
20090176740Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine - Aniracetam (1-[(4-methoxybenzoyl)]-2-pyrrolidinone) is co-administered with the acetylcholine precursor 1-alpha glycerylphosphorylcholine (Alpha GPC, choline alfoscerate, choline alphoscerate) to potentiate cognition enhancing effects in healthy subjects and patients suffering from neurological conditions including Alzheimer's Disease (AD), attention deficit disorder (ADD), Parkinson's Disease, schizophrenia, vascular dementia, post stroke aphasia, anxiety disorders, cerebral atrophy, chronic alcoholism, Down syndrome, dyslexia, and various other neurodegenerative conditions. The co-administration of aniracetam (and other racetam derivatives including oxiracetam) with the acetylcholine precursor 1-alpha glycerylphosphorylcholine decreases negative side-effects such as severe headaches while increasing the synthesis and release of the neurotransmitters acetylcholine and glutamate to facilitate proper brain functioning.07-09-2009
20090221528Therapeutic micro nutrient composition for lipolysis and sclerosis - An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. It also induces an inflammatory reaction which treats disorders of tissue adhesion which often accompany subcutaneous fat deposits or are created in the process of removal of subcutaneous fat deposits. This inflammatory reaction also limits the extent of the effect of the injected medication to a localized area. A lecithin and aqueous sodium chloride based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. Additionally, a program based approach to the treatment of subcutaneous fat deposits which includes injections of this formulation, application of compression garments, diet modification, and exercise is described. The formulation is characterized in that it comprises an adjustable acidifying agent to set pH, an antioxidant, a sclerosing agent, and a stabilizer. It is further characterized in that it includes liposomes, and that the components of these liposomes are therapeutic in the treatment of several human ailments. It is also efficacious in the treatment of striae albicantes, striae atrophicae, cellulite, and decreased skin turgor.09-03-2009
20090239825MULTI-CAROTENOIDS COMPOSITIONS AND USES THEREFOR - Methods for ameliorating the effects of benign prostate hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene, about 0.25% to 2% by weight of phytoene, and about 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising β-carotene, γ-carotene, and δ-carotene, a phytosterol, a tocopheral and a phospholipid. Use of multi-carotenoids compositions for the treatment of urinary tract malfunctions including benign prostate hyperplasia and lower urinary tract symptoms.09-24-2009
20090291919Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity - Methods are disclosed for treating ophthalmic conditions related to the production of toxic visual cycle products that accumulate in the eye, and are associated with reactions of the visual cycle during medical procedures that expose the eye to light, most commonly the various forms of ophthalmic surgery. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said treatments.11-26-2009
20090312285BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM AND METHODS OF USE - Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.12-17-2009
20100029590METHODS FOR TREATING OR PREVENTING HEMORRHAGIC CYSTITIS USING A GLYCEROPHOSPHATE SALT - Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with hem-orrhagic cystitis. Therefore, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using a glycerophosphate salt, hi particular, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using calcium glycerophosphate (CGP).02-04-2010
20100035840PESTICIDAL COMPOSITION COMPRISING FOSETYL-ALUMINIUM, PROPAMOCARB-HCL AND AN INSECTICIDE SUBSTANCE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.02-11-2010
20100137251Functional Role for Cannabinoids in Autonomic Stability During Sleep - The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of cannabimimetic agents and combinations thereof.06-03-2010
20100144674PYRIDAZINE DERIVATIVES - The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R06-10-2010
20100261675FUNGICIDAL COMPOSITION CONTAINING ACID AMIDE DERIVATIVE - Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired. The present invention provides a fungicidal composition containing an acid amide derivative of the formula (I) or a salt thereof, as an active ingredient:10-14-2010
20110015153FLY CONTROL METHOD - This invention relates to a method of treating myiasis of an animal by applying to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, an N-oxide or a pharmaceutically or veterinarily acceptable salts salt thereof01-20-2011
20110021463Method of Treating Citrus Plants to Reduce Bacterial Infections - A method of treating a citrus plant is provided to reduce the incidence of one or more insect-vectored bacterial infections such as citrus greening. The method comprises the step of applying a treatment composition one or more times to the plant, wherein the treatment composition comprises an effective amount of aluminum tris(O-ethyl phosphonate).01-27-2011
20110166105ANTIMICROBIAL WASH AND CARRIER SOLUTIONS AND USES THEREOF - Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.07-07-2011
20120046244DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF - Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.02-23-2012
20120101063BIOCIDAL ALDEHYDE COMPOSITION - A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide, alcohol, and functional excipients for surface-sterilization of medical instruments and other objects. The quaternary phosphonium biocide is preferably TTPC, and the alcohol isopropyl alcohol. The OPA is the dialdehyde C04-26-2012
20120295876PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES - The present invention relates to novel pyridazine derivatives of formula (I) wherein R11-22-2012
20130053344SYNTHESIS OF PYRROLIDINE COMPOUNDS - Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.02-28-2013
20140296185Solid formulations suitable for oilfield applications - The present invention relates to a solid formulation of soap stick type comprising a primary surfactant, at least one binding agent and at least one dispersant that may especially be an amphoteric surfactant, optionally with additives.10-02-2014
20150105349(R)-(-)-1,2-propanediol compositions and methods - Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.04-16-2015
201501118521-Di(sec-butyl)-phosphinoyl-pentane (dapa-2-5) as a topical agent... - The concept is put forward here that heat abstraction sensations, captured by topical application of a molecule, can be used to alleviate discomfort of non-keratinizng tissues. By synthesizing compounds and devising tests, a molecule name DAPA-2-5 was identified as having the selective desirable properties for achieving this purpose. DAPA-2-5 is a di-alkyl-phosphinoyl-alkane, and “DAPA-2-5” is 1-Di(sec-butyl)-phosphinoyl-pentane. DAPA-2-5 evokes a dynamic cooling sensation on non-keratinizing body surfaces (including, e.g., oropharyngeal, esophageal, and anogenital surfaces) which is not accompanied by stinging, irritation, or unpleasant tastes. Thus, it can be used to treat (e.g., suppress) sensory discomfort from non-keratinizing stratified epithelium (NKSE) selectively. This unusual selectivity, potency, and efficacy was also surprisingly exhibited in laboratory animal tests of inhibition of heat-induced edema, of eliciting skin irritation, and of inhibition of acid-induced swallowing. DAPA-2-5 is useful, for example, in the treatment of disorders (e.g., diseases) including sensory discomfort from non-keratinizng stratified epithelial (NKSE) tissue; upper aerodigestive tract discomfort; oropharyngeal discomfort; esophageal discomfort; throat irritation; cough; heartburn; chest pain; anogenital discomfort; or inflammation of non-keratinizng stratified epithelial (NKSE) tissue. The present discovery also pertains to pharmaceutical compositions comprising DAPA-2-5 and DAPA compositions, for example, in therapy and in differential diagnosis. A particularly favoured embodiment is 1-(Di-sec-butyl-phosphinoyl-pentane as an orally disintegrating tablet formulated with a mineral excipient called magnesium aluminosilicate.04-23-2015
20150290029Delivery Systems for Agents to treat Ocular Discomfort - Eye drops are the traditional method for delivering drugs to the ocular surface but this method is considered inefficient and does not work well for soothing agents because sensory discomfort is evoked from the corneal surface by the pulsatile delivery of the agent. By contrast, eye wipes moistened with an evenly dispersed liquid composition of a soothing or cooling agent selectively delivers the active ingredient to receptors in the skin above the eyes, on the edges of the eyelids, and on the conjunctiva and do not evoke eye irritation. The delivered agent is now able to evoke sensations of refreshment and soothing on the ocular surface and to relieve eye discomfort.10-15-2015

Patent applications in class Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI

Patent applications in all subclasses Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI

Website © 2025 Advameg, Inc.